| Business Summary | | Able
Laboratories,
Inc.,
formerly
DynaGen
Inc.,
develops,
makes
and
sells
generic
drugs.
The
Company's
primary
business
activity
is
the
development,
manufacturing
and
marketing
of
generic
drugs
to
its
customers.
Generic
drugs
are
the
chemical
and
therapeutic
equivalents
of
brand-name
drugs.
They
must
meet
the
same
governmental
standards
as
the
brand-name
drugs
they
replace,
and
they
must
meet
all
FDA
guidelines
before
they
can
be
made
or
sold.
The
Company
can
manufacture
and
market
a
generic
drug
only
if
the
patent
or
other
government-mandated
market
exclusivity
period
for
the
brand-name
equivalent
has
expired.
Generic
drugs
are
typically
sold
under
their
generic
chemical
names
at
prices
significantly
below
those
of
their
brand-name
equivalents. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Able
Laboratories,
Inc.,
through
its
subsidiaries,
Superior
Pharmaceutical
Company,
Generic
Distributors,
Inc.
and
Apex
Pharmaceuticals,
develops,
manufactures
and
distributes
generic
pharmaceuticals.
For
the
six
months
ended
6/30/01,
revenues
fell
54%
to
$7.5
million.
Net
loss
applicable
to
Common
totaled
$4.7
million,
up
from
$1.9
million.
Results
reflect
the
disposition
of
GDI
and
Superior,
reduced
gross
and
operating
margins
and
a
$1.8
million
increase
in
preferred
stock
expenses. | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| C. Robert Cusick, 54 Chairman,
CEO | -- | Dhananjay Wadekar, 47 Pres,
Treasurer, Sec., Director | $145K | Catherine Bardwick-Frost VP
of Investor Relations | -- | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|